<DOC>
	<DOCNO>NCT00948402</DOCNO>
	<brief_summary>Insulin-resistance play important role polycystic ovary syndrome ( PCOS ) physiopathology . The phosphoprotein enrich diabetes ( PED/PEA-15 ) , 15 kDa protein related insulin sensitivity , over-expressed type 2 diabetic patient PCOS woman , independently obesity . The effectiveness oral contraceptive pill ( OCP ) metformin ( MET ) PCOS management still uncertain . Aim pilot clinical study compare effect OCPs MET expression PED/PEA-15 association insulin sensitivity obese PCOS woman . Outcome measure : PED/PEA-15 , BMI , plasma glucose insulin , 1/HOMA-IR , homeostasis model assessment insulin resistance ; QUICKI , quantitative insulin sensitivity check index ; ISI : whole-body insulin sensitivity index . Study design : twenty obese PCOS woman ( age : 24.7±18 yr ; BMI : 30±2.4 kg/m2 ) randomize accord insulin sensitivity receive 30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month MET 1250 mg three time daily 6 month . Results : At baseline , age BMI different two group ; PED/PEA-15 protein expression high MET OCP group ( p=0.011 ) , along high 1/HOMA-IR ( p=0.004 ) , low QUICKI ISI ( p=0.003 p &lt; 0.001 , respectively ) . After treatment , independently body weight , MET group PED/PEA-15 decrease ( p=0.004 ) , along insulin 1/HOMA-IR ( p &lt; 0.001 ) , QUICKI ISI increase ( p &lt; 0.001 ) . Insulin sensitivity index improvement correlate significantly PED/PEA-15 protein expression , BMI . Conclusions : PED/PEA-15 protein over-expression obese PCOS woman IR reduce six month treatment MET , remain unchanged OCP group . The reduction independent body weight , correlate insulin sensitivity index . This effect support MET effective therapy OCPs obese PCOS woman IR , also fertility require .</brief_summary>
	<brief_title>PED/PEA-15 Protein , PCOS , Obesity , Insulin Sensitivity Indexes , Metformin , Oral Contraceptives</brief_title>
	<detailed_description>Subjects : Twenty obese PCOS woman ( age : 24.7±18 yr ; BMI : 30±2.4 kg/m2 ) consecutively admit Endocrinology Unit Department Molecular Clinical Endocrinology Oncology Federico II University Naples , enrol clinical study . The diagnosis PCOS make accord diagnostic criterion PCOS At study entry patient randomize two group treatment , accord insulin sensitivity . OCP group , 10 patient ( BMI 29.7± 1.5 kg/m2 ) receive 30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month . MET group , 10 patient ( BMI 30.4± 3.1 kg/m2 ) , receive metformin 1250 mg three time daily . The duration follow-up 6 month . The control group consist 10 healthy female volunteer , age match . Methods : As PCOS woman anovulatory , underwent progesterone challenge test ( 100 mg natural progesterone i.m . ; Prontogest , Amsa , Rome , Italy ) , induced uterine bleed PCOS woman . To exclude presence type 2 diabetes abnormal glucose tolerance , oral glucose tolerance test ( OGTT ) perform normal glucose response OGTT define accord 'Report Expert Committee diagnosis classification diabetes mellitus ' . All anthropometric measurement take subject wear light clothes without shoe . In woman , weight height measure calculate BMI [ weight ( kg ) divide height square ( m2 ) , kg/m2 ] . Height measure near cm use wall-mounted stadiometer . Body weight ( BW ) determine near 50 g use calibrate balance beam scale . Patients give standardized interview obtain information duration obesity , eat pattern , smok¬ing habit physical exercise . In particular , subject also ask make daily record amount physical activity ( exercise ; ≤2-3 h/week ; ≥2-3 h/week ) . Preadmission food intake dietary history assess skilled dietitian use computer-assisted interview ( Winfood 1.5 , Medimatica srl , Martinsicuro , Italy ) . All PCOS woman receive normo-caloric diet . Assays : Blood sample obtain 08.00 h 09.00 h antecubital vein overnight fast , patient rest position . The OGTT perform use 75 g dextrose . Blood sample obtain 0 , 30 , 60 , 90 , 120 , min plasma glucose insulin measurement . Fasting plasma glucose ( FPG ) level determine glucose oxidase method immediately OGTT . Fasting plasma insulin ( FPI ) sample promptly centrifuge , plasma separate stored -20°C assay . FPI measure solid-phase chemiluminescent enzyme immunoassay use commercially available kit ( Immunolite Diagnostic Products Co , Los Angeles , CA ) . 1/HOMA-IR , QUICKI ISI calculate . PED/PEA-15 protein measure white-blood cell ( WBC ) lysates obtain 10 12 ml freshly collect uncoagulated whole blood , separation dextran 6 % , use Western blot analysis . For Western blot analysis WBC solubilized 4°C TAT buffer , centrifuge 500g 20 min , supernatant fraction store -20°C use . The amount 50 μg lysate protein heat 100°C Laemmli buffer . Proteins separate 15 % SDS-PAGE transferred 0•45-mm Immobilon-P membrane ( Millipore , Bedfort , MA ) . Filters probe PED/PEA-15 antiserum 1:2000 dilution , reveal enhanced chemiluminescence autoradiography . The protein band quantify laser densitometry express percentage pixel ( arbitrary unit ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>female premenopausal obesity PCOS . pregnancy type 2 diabetes impair glucose tolerance hypothyroidism hyperprolactinaemia Cushing 's syndrome nonclassical congenital adrenal hyperplasia previous ( within last 6 month ) use oral contraceptive glucocorticoid antiandrogens ovulation induction agent antidiabetic antiobesity drug , hormonal drug . None subject affect neoplastic , metabolic , hepatic , cardiovascular disorder concurrent medical illness ( i.e . diabetes , renal disease , malabsorptive disorder ) , acute chronic inflammation base medical history , physical examination , routine laboratory test , include measurement oral temperature , white blood cell count urinalysis .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>28 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>PED/PEA-15 protein</keyword>
	<keyword>PCOS</keyword>
	<keyword>IR</keyword>
	<keyword>metformin</keyword>
	<keyword>OCP</keyword>
	<keyword>Oral Contraceptive</keyword>
</DOC>